Insys Therapeutics CFO Darryl S. Baker Unloads 10,000 Shares (INSY)
Insys Therapeutics (NASDAQ:INSY) CFO Darryl S. Baker sold 10,000 shares of the stock on the open market in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $47.54, for a total value of $475,400.00. Following the transaction, the chief financial officer now directly owns 3,125 shares of the company’s stock, valued at approximately $148,563. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Insys Therapeutics (NASDAQ:INSY) traded up 2.06% on Wednesday, hitting $48.00. 170,554 shares of the company’s stock traded hands. Insys Therapeutics has a 52 week low of $7.10 and a 52 week high of $53.64. The stock has a 50-day moving average of $42.17 and a 200-day moving average of $33.67. The company has a market cap of $1.031 billion and a price-to-earnings ratio of 9.70.
Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.58 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.33 by $0.25. The company had revenue of $29.20 million for the quarter, compared to the consensus estimate of $27.00 million. During the same quarter in the prior year, the company posted ($0.32) earnings per share. The company’s quarterly revenue was up 508.3% on a year-over-year basis. Analysts expect that Insys Therapeutics will post $1.33 EPS for the current fiscal year.
A number of research firms have recently commented on INSY. Analysts at Zacks downgraded shares of Insys Therapeutics from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, November 19th. They now have a $49.00 price target on the stock. Analysts at JMP Securities raised their price target on shares of Insys Therapeutics from $30.00 to $50.00 in a research note to investors on Tuesday, November 12th. They now have a “market outperform” rating on the stock.
Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.